Medical Centre Nevromedics EOOD

The centre’s cardiovascular program evaluates innovative treatments for heart failure across the spectrum of ejection fraction, investigates agents that lower the risk of major adverse cardiovascular events, and explores blood‑pressure‑lowering strategies.

• Heart failure with reduced ejection fraction
• Heart failure with preserved ejection fraction
• Atherosclerotic cardiovascular disease and high cardiovascular risk
• Hypertension management
• Combination therapy with empagliflozin and vicadrostat

With 14 active trials and a team of three investigators, Medical Centre Nevromedics EOOD in Veliko Tirnovo contributes significantly to European cardiovascular research.

At present, the site does not host active studies specifically targeting congenital or hereditary disorders, but it retains the capacity to support such protocols when opportunities arise.

• Preparedness for rare genetic disease trials
• Potential inclusion of hereditary cardiomyopathies
• Infrastructure for neonatal research collaborations

The facility remains equipped to expand into this therapeutic area while continuing its broader clinical research agenda.

The metabolic portfolio focuses on conditions such as severe hypertriglyceridemia and obesity, evaluating novel lipid‑lowering agents and weight‑management therapies to improve overall metabolic health.

• Severe hypertriglyceridemia
• Obesity and overweight management
• Non‑diabetic chronic kidney disease linked to metabolic risk
• Fasting triglyceride reduction studies
• Body‑weight reduction interventions

These studies aim to demonstrate efficacy and safety of emerging treatments, contributing to better management of metabolic disorders.

Research on respiratory tract infections is centered on evaluating antiviral compounds for acute respiratory syncytial virus, with the goal of shortening illness duration and preventing severe complications.

• Respiratory syncytial virus (RSV) infection in adults
• High‑risk RSV patients
• Antiviral efficacy of S‑337395
• Safety assessment of EDP‑938
• Symptomatic non‑hospitalized RSV cases

The trials are designed to determine how new antivirals can improve outcomes for patients with RSV, a leading cause of respiratory illness.

The centre’s virology studies address viral respiratory illnesses, particularly RSV, by measuring how investigational agents influence viral replication and clinical progression.

• RSV antiviral trials
• Evaluation of viral load reduction
• Placebo‑controlled RSV studies
• Management of high‑risk viral infections
• Exploration of novel antiviral mechanisms

Findings from these studies aim to expand therapeutic options for viral diseases and support public health efforts in Europe.